Clinical trials: CNS Germ Cell Tumor
Brain Cancer, MALIGNANT GLIOMA
Hypofractionated Stereotactic Radiotherapy With Bevacizumab in the Treatment of Recurrent Malignant Glioma
The best dose of radiation to be given with bevacizumab is currently unknown. This study will use higher doses of radiation with bevacizumab than have been used before.
- Conditions
- Brain Cancer, MALIGNANT GLIOMA, Glioblastoma, Anaplastic Astrocytoma (AA)
- Trial name
- NCT01392209
- Testing
- Bevacizumab & Stereotactic Radiotherapy
- Where
- 5 sites in United States
- Volunteers
- 15 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Medulloblastoma
Multicenter Pilot-study for the Therapy of Medulloblastoma of Adults
The purpose of this study is to determine whether a combination of a radiochemotherapy (vincristin) and a following maintenance chemotherapy (vincristin, cisplatin and CCNU) in adult patients with medulloblastoma is tolerable.
- Trial name
- NOA-07 (NCT01614132)
- Testing
- maintenance chemotherapy (vincristin, cisplatin and CCNU), Radiotherapy
- Where
- 15 sites in Germany
- Volunteers
- 33 people
- Sponsor
- University of Regensburg
Brain and Central Nervous System Tumors
Carboplatin in Patients With Progressive Gliomas
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of carboplatin in patients with progressive glioma.
- Trial name
- NCT00002749
- Testing
- carboplatin
- Where
- 2 sites in United States, Canada
- Volunteers
- 25 people
- Sponsor
- Duke University
Brain and Central Nervous System Tumors
Lymphokine-Activated Killer Cells or Gliadel Wafer in Treating Patients With Newly Diagnosed Glioblastoma Multiforme That Can Be Removed by Surgery
RATIONALE: Biological therapies, such as lymphokine-activated killer cells, may stimulate the immune system in different ways and stop tumor cells from growing.
- Trial name
- NCT00814593
- Testing
- lymphokine-activated killer cells, polifeprosan 20 with carmustine implant
- Where
- United States
- Sponsor
- Lisata Therapeutics, Inc.
CNS Malignancies, Medulloblastoma Recurrent
A Phase 0/1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refractory CNS Malignancies.
This clinical trial is studying a drug called SGT-53 along with radiation and another drug called Nivolumab. It's for children with brain tumors that have come back, gotten worse, or didn't get better with earlier treatments.
- Conditions
- CNS Malignancies, Medulloblastoma Recurrent, ATRT Recurrent, Pineoblastoma
- Trial name
- JACOB (NCT07017816)
- Testing
- SGT-53, hypofractionated radiotherapy with immunotherapy, Nivolumab
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Children's National Research Institute
Brain and Central Nervous System Tumors
Irinotecan in Treating Patients With Progressive or Recurrent Malignant Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of irinotecan in treating patients who have progressive…
- Trial name
- NCT00003616
- Testing
- irinotecan hydrochloride
- Where
- 10 sites in United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Brain and Central Nervous System Tumors
Olaparib and Temozolomide in Treating Patients With Relapsed Glioblastoma
RATIONALE: Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by…
- Trial name
- NCT01390571
- Testing
- olaparib, temozolomide, gene expression analysis
- Where
- 7 sites in United Kingdom
- Volunteers
- 34 people
- Sponsor
- Cancer Research UK
Glioblastoma, Respiratory Distress Syndrom
NuvOx Expanded Access
NanO₂ is an investigational drug being studied by NuvOx Therapeutics. It has not been approved by the U.S. Food and Drug Administration (FDA) for any use.
- Conditions
- Glioblastoma, Respiratory Distress Syndrom, Ischemic Stroke, Hypoxic Conditions
- Trial name
- NCT07748299
- Testing
- NanO₂
- Sponsor
- NuvOx LLC
Advanced Malignant Solid Neoplasm, Recurrent Ependymoma
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH trial studies how well larotrectinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with NTRK fusions that may have spread from where it first started to…
- Conditions
- Advanced Malignant Solid Neoplasm, Recurrent Ependymoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Glioma
- Trial name
- NCT03213704
- Testing
- Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan
- Where
- 124 sites in United States, Puerto Rico
- Volunteers
- 9 people
- Sponsor
- National Cancer Institute (NCI)
Diffuse Intrinsic Pontine Glioma
MTX110 by Convection-Enhanced Delivery in Treating Participants With Newly-Diagnosed Diffuse Intrinsic Pontine Glioma
This phase I/II trial studies the side effects of panobinostat nanoparticle formulation MTX110 (MTX110) in treating participants with newly-diagnosed diffuse intrinsic pontine glioma.
- Trial name
- PNOC015 (NCT03566199)
- Testing
- Panobinostat Nanoparticle Formulation MTX110, Convection-Enhanced Delivery (CED)
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Sabine Mueller, MD, PhD
Brain and Central Nervous System Tumors, Lymphoma
Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
RATIONALE: Gene therapy may improve the body's ability to fight cancer or make the cancer more sensitive to chemotherapy. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or…
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00003567
- Testing
- filgrastim, sargramostim, therapeutic autologous lymphocytes
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Case Comprehensive Cancer Center
Melanoma and Brain Metastases
Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites
This is a global, multi-centre, open-label, study of GSK2118436 conducted in up to 30 evaluable subjects with resectable, BRAF V600E or V600K mutation-positive metastatic melanoma to the brain.
- Trial name
- NCT01978236
- Testing
- Dabrafenib 150 mg, Trametinib 2.0 mg
- Where
- 3 sites in United States, Australia
- Volunteers
- 6 people
- Sponsor
- GlaxoSmithKline
Brain and Central Nervous System Tumors
Carmustine Wafers Plus Irinotecan in Treating Patients With Recurrent Supratentorial High Grade Gliomas
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003463
- Testing
- carmustine, irinotecan hydrochloride, polifeprosan 20 with carmustine implant
- Where
- 2 sites in United States
- Sponsor
- Duke University
Brain Cancer, Brain Tumor
Natural History of and Specimen Banking for People With Tumors of the Central Nervous System
Background: Brain and spinal cord tumors are uncommon. But they contribute substantially to cancer deaths in the U.S. in children and adults. Little progress has been made in treating brain tumors.
- Conditions
- Brain Cancer, Brain Tumor, Spine Cancer, Spine Tumor
- Trial name
- NCT02851706
- Testing
- No Treatment
- Where
- United States
- Volunteers
- 1,214 people
- Sponsor
- National Cancer Institute (NCI)
Childhood Choroid Plexus Tumor, Childhood Medulloblastoma
Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer
This randomized phase III trial studies flexible administration of filgrastim after combination chemotherapy to see how well it works compared to fixed administration of filgrastim in decreasing side effects of chemotherapy in…
- Conditions
- Childhood Choroid Plexus Tumor, Childhood Medulloblastoma, Childhood Pineoblastoma, Childhood Soft Tissue Sarcoma
- Trial name
- NCT01987596
- Testing
- filgrastim
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Brain and Central Nervous System Tumors
Nitrocamptothecin in Treating Patients With Glioblastoma Multiforme
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of nitrocamptothecin in treating patients who have…
- Trial name
- NCT00005826
- Testing
- rubitecan
- Where
- 13 sites in Belgium, France and 4 more
- Volunteers
- 17 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Hematological Neoplasms, Non-Hodgkin's Lymphoma
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
This is a Phase 1, open-label, multicenter, randomized, 2-stage crossover study consisting of 2 phases: Stage I - Pharmacokinetics (Bioequivalence), with an Extension Stage II - Pharmacokinetics (Food Effect) with an Extension…
- Conditions
- Hematological Neoplasms, Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Lymphoma
- Trial name
- NCT02223052
- Testing
- CC-486, Vidaza
- Where
- 10 sites in United States
- Volunteers
- 89 people
- Sponsor
- Celgene
Adrenocortical Carcinoma, Brain and Central Nervous System Tumors
Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as cisplatin and doxorubicin, work in different ways to stop tumor cells from dividing so they stop growing or die. Estrogen can stimulate the growth of tumor cells.
- Conditions
- Adrenocortical Carcinoma, Brain and Central Nervous System Tumors, Head and Neck Cancer, Liver Cancer
- Trial name
- NCT00002608
- Testing
- cisplatin, doxorubicin hydrochloride, tamoxifen citrate
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Ottawa Regional Cancer Centre
Diffuse Intrinsic Pontine Glioma, Diffuse Pontine and Thalamic Gliomas
CED of MTX110 Newly Diagnosed Diffuse Midline Gliomas
The blood brain barrier (BBB) prevents some drugs from successfully reaching the target source. Convection-Enhanced Delivery (CED) is a method of direct infusion of drugs under controlled pressure to the tumor that may reduce…
- Conditions
- Diffuse Intrinsic Pontine Glioma, Diffuse Pontine and Thalamic Gliomas, Diffuse Midline Glioma
- Trial name
- NCT04264143
- Testing
- Infusate with MTX110 and gadolinium, Convection-Enhanced Delivery (CED)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Luca Szalontay
Giant Cell Glioblastoma, Glioblastoma
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
This partially randomized phase II trial with a safety run-in component studies the side effects and how well bevacizumab given with or without trebananib works in treating patients with brain tumors that have come back…
- Conditions
- Giant Cell Glioblastoma, Glioblastoma, Gliosarcoma, Oligodendroglioma
- Trial name
- NCT01609790
- Testing
- Bevacizumab, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 244 sites in United States, Canada
- Volunteers
- 137 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.